Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term progression-free survival with degarelix vs goserelin in prostate cancer requiring androgen deprivation therapy
2010-021434-55Phase 3Terminated
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of degarelix and goserelin in prostate cancer (PCa) (2 arms), sponsored by Ferring Pharmaceuticals. Started Sep 2010; status: terminated.
02
Drugs
degarelixgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021434-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021434-55.